Recent Finacing
Recent Raise
Tracon Pharmaceuticals develops targeted therapies for cancer and age-related macular degeneration, advancing monoclonal antibody TRC105 (anti-endoglin) and small molecule TRC102 through Phase 1b/2 clinical trials across multiple solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
